

6 3
18. The method of claim ~~9~~³, wherein said cell is capable of undergoing necrosis in the presence of zVAD-fmk and DMSO.

7 3
19. The method of claim ~~9~~³, wherein said cell is mammalian.

11 3
23. The method of claim ~~9~~³, wherein said compound is in a pharmaceutically acceptable carrier.

14 12
32. The method of claim ~~24~~¹², wherein said condition is a neurodegenerative disease.

16 12
34. The method of claim ~~24~~¹², wherein said condition is selected from the group consisting of ischemic brain injury, ischemic heart injury, and head trauma.

17 12
35. The method of claim ~~24~~¹², wherein said subject is a mammal.

Support for the Amendments


The claims have been amended to reflect the invention of Group I elected herewith. No new matter is introduced by any of these amendments. A "marked up" version of the amended claims, showing the changes made, is attached.

If there are any charges, or any credits, please apply them to Deposit Account No.

03-2095.

Respectfully submitted,

Date: May 10, 2001


Kristina Bieker-Brady, Ph.D.
Reg. No. 39,109

RECEIVED

MAY 16 2001

TECH CENTER 1600/2900

Clark & Elbing LLP
176 Federal Street
Boston, MA 02110
Telephone: 617-428-0200
Facsimile: 617-428-7045



21559

PATENT TRADEMARK OFFICE

00742.056003 Reply to Restriction Requirement.wpd